雌激素受体阴性人类乳腺癌的潜在生物标志物和靶点。
Putative biomarkers and targets of estrogen receptor negative human breast cancer.
作者信息
Sahab Ziad J, Man Yan-Gao, Byers Stephen W, Sang Qing-Xiang A
机构信息
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA; E-Mail:
出版信息
Int J Mol Sci. 2011;12(7):4504-21. doi: 10.3390/ijms12074504. Epub 2011 Jul 13.
Breast cancer is a progressive and potentially fatal disease that affects women of all ages. Like all progressive diseases, early and reliable diagnosis is the key for successful treatment and annihilation. Biomarkers serve as indicators of pathological, physiological, or pharmacological processes. Her2/neu, CA15.3, estrogen receptor (ER), progesterone receptor (PR), and cytokeratins are biomarkers that have been approved by the Food and Drug Administration for disease diagnosis, prognosis, and therapy selection. The structural and functional complexity of protein biomarkers and the heterogeneity of the breast cancer pathology present challenges to the scientific community. Here we review estrogen receptor-related putative breast cancer biomarkers, including those of putative breast cancer stem cells, a minor population of estrogen receptor negative tumor cells that retain the stem cell property of self-renewal. We also review a few promising cytoskeleton targets for ER alpha negative breast cancer.
乳腺癌是一种渐进性且可能致命的疾病，影响着所有年龄段的女性。与所有渐进性疾病一样，早期且可靠的诊断是成功治疗和根除的关键。生物标志物可作为病理、生理或药理过程的指标。人表皮生长因子受体2/神经（Her2/neu）、癌抗原15.3（CA15.3）、雌激素受体（ER）、孕激素受体（PR）和细胞角蛋白都是已获美国食品药品监督管理局批准用于疾病诊断、预后评估及治疗选择的生物标志物。蛋白质生物标志物的结构和功能复杂性以及乳腺癌病理的异质性给科学界带来了挑战。在此，我们综述与雌激素受体相关的假定乳腺癌生物标志物，包括假定的乳腺癌干细胞的生物标志物，这是一小部分保留自我更新干细胞特性的雌激素受体阴性肿瘤细胞。我们还综述了一些针对雌激素受体α阴性乳腺癌有前景的细胞骨架靶点。
Zotero 插件